TriSalus Life Sciences, Inc.
TLSI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $29,431 | $18,511 | $12,398 | $8,401 |
| % Growth | 59% | 49.3% | 47.6% | – |
| Cost of Goods Sold | $4,103 | $2,605 | $2,258 | $1,193 |
| Gross Profit | $25,328 | $15,906 | $10,140 | $7,208 |
| % Margin | 86.1% | 85.9% | 81.8% | 85.8% |
| R&D Expenses | $17,688 | $29,835 | $21,358 | $14,224 |
| G&A Expenses | $17,966 | $23,512 | $12,483 | $8,753 |
| SG&A Expenses | $43,805 | $40,546 | $25,221 | $17,016 |
| Sales & Mktg Exp. | $25,839 | $17,034 | $12,738 | $8,263 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $61,493 | $70,381 | $46,579 | $31,240 |
| Operating Income | -$36,165 | -$54,475 | -$36,439 | -$24,032 |
| % Margin | -122.9% | -294.3% | -293.9% | -286.1% |
| Other Income/Exp. Net | $6,126 | -$4,879 | -$10,739 | -$4,810 |
| Pre-Tax Income | -$30,039 | -$59,354 | -$47,178 | -$28,842 |
| Tax Expense | $6 | $9 | $9 | $3 |
| Net Income | -$33,233 | -$59,363 | -$47,187 | -$28,845 |
| % Margin | -112.9% | -320.7% | -380.6% | -343.4% |
| EPS | -1.25 | -2.23 | -1.59 | -0.92 |
| % Growth | 43.9% | -40.3% | -72.8% | – |
| EPS Diluted | -1.25 | -2.23 | -1.59 | -0.92 |
| Weighted Avg Shares Out | 26,502 | 26,466 | 29,608 | 31,250 |
| Weighted Avg Shares Out Dil | 26,502 | 26,466 | 29,608 | 31,250 |
| Supplemental Information | – | – | – | – |
| Interest Income | $404 | $431 | $180 | $0 |
| Interest Expense | $3,090 | $16 | $1 | $1,761 |
| Depreciation & Amortization | -$3,036 | $684 | $414 | $464 |
| EBITDA | -$36,165 | -$58,654 | -$46,763 | -$23,568 |
| % Margin | -122.9% | -316.9% | -377.2% | -280.5% |